Clinical trial
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
NCT00471536 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00471536 |
|---|---|
| Title | Pazopanib in Treating Patients With Metastatic Urothelial Cancer |
| Official title | A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer |
| Intervention type | Drug |
| Interventions | pazopanib hydrochloride |
| Enrollment | 19 |
| Start date | Aug 1, 2008 |
| Primary completion | Jul 1, 2010 |
| Completion | Dec 1, 2013 |
| First posted | May 10, 2007 |
| Last update posted | May 30, 2014 |
| Countries | China, South Korea, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: